Pricing and Access Archives

Blog

Solving the Cell & Gene Therapy Access Puzzle in the U.S.

January 10, 2025

Cell and gene therapies (CGTs) have ushered in a new era of medicine, offering patients transformative, even potentially curative solutions, with a single treatment. Despite the clinical promise, barriers to patient access remain given administration complexity, gaps in patient outcome evidence...

Blog

5 Key Trends in Global Market Access

December 12, 2024

Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various...

Blog

IRA “Negotiations” Price Release: No Big Surprises, But Is the Industry Ready Today and for the Future?

August 16, 2024

Yesterday, CMS released the results of the first round of “negotiated” prices for the Inflation Reduction Act (IRA).1 The IRA is a historical landmark legislation for the pharmaceutical industry, and the results from these “negotiations” involving 10 of the top Medicare...

Blog

Developing Effective Global Value Dossiers

June 13, 2024

Trinity Life Sciences recently worked with a large global pharma company to develop a new process for creating global value dossiers (GVDs) that better met the needs of regional affiliates. Matt O’Hara, who leads Trinity’s Evidence Strategy practice, shares insights into...

Blog

Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future

May 23, 2024

Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which...

Blog

Rise with the Waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future

April 22, 2024

Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to...

Blog

Rise with the Waves: Canada – A Coming (R)evolution: Transforming Pharmaceutical Market Access

April 5, 2024

Executive Summary Canada has undertaken meaningful strategies to transform patient access and ultimately improve health outcomes across the country. Two such potentially high-impact strategies include the planned transformation of the former Canadian Agency for Drugs and Technology in Health (CADTH) into...

Blog

Using Transparency in Coverage Reimbursement Insights to Inform Payer and Provider Contracting Strategy

April 5, 2024

Executive Summary “Transparency in Coverage” (TIC) data is a newer data source that has recently become available for mining unique insights in the reimbursement/economics between payers and providers. In 2020, the Federal Government TIC Rule required health insurers and group health...

Blog

Rise with the Waves: Italy – AIFA Restructuring and Budget Reforms – Stepping into a New (Uncertain) Future?

March 20, 2024

Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the...